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a b s t r a c t
Improvements in health care and lifestyle have led to an elevated lifespan and increased focus on age-
associated diseases, such as neurodegeneration, cardiovascular disease, frailty and arteriosclerosis. In all
these chronic diseases protein, lipid or nucleic acid modiﬁcations are involved, including cross-linked
and non-degradable aggregates, such as advanced glycation end products (AGEs). Formation of
endogenous or uptake of dietary AGEs can lead to further protein modiﬁcations and activation of
several inﬂammatory signaling pathways. This review will give an overview of the most prominent AGE-
mediated signaling cascades, AGE receptor interactions, prevention of AGE formation and the impact of
AGEs during pathophysiological processes.
& 2014 The Authors. Published by Elsevier B.V. All rights reserved.
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Introduction
The pursuit of immortality and eternal youth has fascinated
people for thousands of years and led to a growing interest in
aging and clinical research. Since 1840 life expectancy has
increased enormously and according to statistics will increase
further to 90 years until 2050 [1]. Over the past few decades
improvements in health care (including managements of infec-
tious diseases) and supply of nutritional compounds are the main
reasons for the increasing lifespan. But the older people get, the
higher the risk of acquirement of age-related diseases is. As a
result, the number of age-associated and chronic diseases has
increased constantly [2]. In addition to the rising age, a worldwide
rapid increase in Western lifestyle—including elevated consump-
tion of highly processed food and sugar, smoking as well as little
physical activity already in the young generation—increases the
incidence in chronic diseases [3–6]. In particular, neurodegenera-
tive and cardiovascular diseases play the most important roles in
limiting quality of life of the aging population. Furthermore, the
main problem is that such diseases are no longer limited to elderly
people. More often, young and middle-aged people are affected by
such diseases, resulting in reduced working capacity, loss of life
quality and a ﬁnancial burden for the healthcare system. A lot of
chronic diseases are associated with accumulation of age-related
modiﬁed biomolecules. Normally, cell constituents which are no
longer functional are repaired or removed by cellular defense
mechanisms. Aggravated by the fact that endogenous repair and
degradation systems become increasingly impaired during the
aging process, damaged and dysfunctional cell components can
accumulate and become non-degradable. In the process of normal
aging, a gradual accumulation of modiﬁed proteins, lipids and
nucleic acids in body ﬂuids or cells is not unusual. Elevated levels
of damaged and accumulated proteins are responsible for forming
bulky aggregates and plaques that are common for neurodegen-
erative and vascular diseases [7,8]. An increase of oxidative stress
during aging promotes further protein modiﬁcations and leads to
the impairment of defense mechanisms over time [9–13]. Addi-
tionally, it is believed that high intake of glucose and fat, due to the
Western diet, accelerate the development of chronic diseases, such
as arteriosclerosis, sarcopenia, cataracts, Parkinson0s disease, vas-
cular dementia and diabetes [14–18]. Furthermore, genetic pre-
disposition and increasing amounts of environmental reactive
substances, such as xenobiotics, pharmaceuticals and toxins also
have the ability to accelerate chronic diseases [19] Consequently, a
lot of different causes may be responsible for the modiﬁcation of
biomolecules. Protein glycation, oxidation and nitration are the
most important non-enzymatic protein modiﬁcations involved in
the formation of endogenous protein aggregates.
At the moment one of the best studied substance classes is the
heterogeneous group of advanced glycation end products. The
spontaneous discovery of AGEs goes back to the investigation of
the non-enzymatic browning reaction by Maillard in 1912 [20].
He was the ﬁrst to observe and describe brown-colored end
products after the reaction of glucose with the amino acid glycin.
Today, AGEs are widely used by the food industry to improve taste,
safety and bioavailability of food [21]. The formation of AGEs
during food preparations is a very fast procedure, given that
formation of AGEs rises in parallel to the increasing temperature
and sugar concentration. Due to the lower temperature, AGE
formation in vivo is a prolonged process. It is in general believed
that the long-term formation of AGEs in vivo affects especially
long-lived proteins, such as hemoglobin, alkaline phosphatase,
lysozyme, collagen or elastin [22,23]. In the case of collagen, AGE
cross-links are responsible for stiffening of the extracellular matrix
(ECM) and often involved in organ and vessel dysfunction [24]. In
addition to their long biological half-life, they are also directly
exposed to the high extracellular glucose levels and therefore an
appropriate target. This glycation results in alteration of protein
structure and makes them more resistance to degradation pro-
cesses, ending in the accumulation of cross-linked products in
cells and body tissues [23]. Due to the amount of reactive
substances that can cause cellular modiﬁcations, this review
focuses primarily on role of AGEs in cellular signaling. Different
precursors, arising out of glycation or lipid peroxidation are
responsible for the formation of endogenous advanced glycation
end products in vivo.
Formation of advanced glycation end products
During the aging process but also increasingly in young gen-
erations, a rise in blood glucose levels due to the Western lifestyle
is no longer an uncommon feature. Over the years, elevated blood
glucose levels will lead to insulin deﬁciency, resulting in hyper-
glycemia, kidney disease and eye disorders, the main secondary
diseases of diabetes type 2. Apart from increased blood glucose
levels, an increase in intra- and extracellular stress is also crucial
for such diseases.
In addition, there are several studies which demonstrating a
positive effect on metabolism by mild oxidative stress [25–27].
Throughout phagocytosis ROS play a crucial role in the defense of
pathogens, suggesting the protective effect of mild doses of
oxidative stress [28]. However, elevated levels of ROS lead to
oxidation of proteins, lipids and nucleic acids increases. Normally,
there is a balance between oxidants and antioxidant defense.
During aging, the equilibrium of prooxidants and antioxidants
shifts to the former, leading to a marked rise in reactive oxygen
species (ROS). Usually, oxidized proteins are degraded by the 20S
proteasome of the Ubiquitin–Proteasome-System (UPS) [29–31].
Located in the cytosol and nucleus of each cell, it is responsible for
the degradation of short-lived and unfolded oxidized proteins.
The cylindrical proteasome consists of two main parts, two outer
α-rings for binding the substrate and two inner β-rings responsible
for the proteolytic activity. Formation of cross-linked proteins, can
cause inhibition of the UPS [31]. Due to their bulky structure, AGEs
are able to block the entry of the proteasomal core [20,32,33].
The resulting decrease in proteolytic activity leads to an increase
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in oxidized and damaged proteins [21,34,35], which can promote
further protein modiﬁcation [2]. Further, elevated levels of
oxidants promote the oxidation of lipids and glucose, resulting
in the accelerated formation of AGEs. Alterations of extracellular
proteins, such as collagen and elastin as well as the activation of
different signaling pathways after intracellular uptake are the
consequences of increasing AGE levels. Besides the proteasome,
other enzymes of the cellular repair mechanisms are also affected
by excessive ROS levels, resulting in a decline of antioxidative and
repair potential of the cells. Consequently increasing levels of
advanced glycation end products support the formations of
reactive oxygen and nitrogen species which in turn induce
further formation of AGEs. Thus, ﬁrst reaction in the formation
of AGEs is the condensation of the carbonyl group of a reducing
sugar or aldehyde with a free amino group of a protein (Fig. 1). In
the following, a reversible Schiff0 base (aldimin) is formed, which
can be in turn transformed into a covalently-bound Amadori
product. The rearrangement of aldimins depends on the amount
of glucose, free amino groups of the proteins as well as an
alkaline pH value. In contrast, Amadori rearrangements proceed
at an acidic pH value and have a slower reaction rate. The
glycated hemoglobin (HbA1c) was one of the ﬁrst known Amadori
products. It is used as a suitable marker for average blood glucose
levels and measurable in the blood up to three weeks. For the
most long-lived proteins, as hemoglobin, the Amadori reaction is
still reversible.
To generate the ﬁnal and irreversible AGEs, further reactions
must follow [36]. Amadori rearrangement not only occurs via
oxidative processes but also in non-oxidative reactions, like
reordering of functional groups and hydrolysis [37]. The formation
of AGEs from autoxidation of Amadori products is known as
Hodge-pathway (Fig. 2). The combination of increased blood
glucose, oxidative and non-oxidative processes result in rearran-
gements of the Amadori products into the irreversible advanced
glycation end products [3,17]. But not only Amadori products
are responsible for the AGE-formation. In addition, lipid and
amino acid degradation, cleavage of dicarbonyl compounds from
aldimins (Namiki pathway) as well as the formation of carbonyl-
compounds after autoxidation of monosaccharaides; such as
glucose, ribose, fructose and glyceraldehyde (Wolff pathway)
[38]; can lead to the development of AGE compounds [39,40]
(Fig. 2). In the deﬁnition of in vivo-formed AGEs, these compounds
are divided into two groups according to their origin: advanced
glycation end products deriving from protein–carbonyl reactions
(AGEs) or advanced lipoxidation end products (ALEs). While
former arise from non-enzymatic glycation, autoxidation of glu-
cose or from the sorbitol-pathway, ALEs are generated by reactive
dicarbonyl compounds (RCC) arising from lipid peroxidation. In
further course of this review both will be summarized under the
term AGE. In vivo lipid peroxidation is the main source of carbonyl
compounds called α-oxoaldehydes (Fig. 1). The reaction takes
places when polyunsaturated fatty acids, main components of
biological membranes, are attacked by ROS. The resulting pro-
ducts, such as the peroxyl radical are highly reactive and lead to
further oxidation, generating lipid hydroperoxides and hydrogen
peroxide [41]. Resulting products of this further oxidation are
reactive carbonyl species (RCS) such as malondialdehyde (MDA),
4-hydroxy-trans-2-nonenal (HNE) and α-oxoaldehydes, such as
glyoxal, methylglyoxal, 3-deoxyglucuson and acrolein [3,37,42].
In addition to further rearrangements, RCS can lead to AGEs such
as Nε-carboxyethyllysine (CEL), arginine pyrimidine, pentosidine,
pyrralin, methylglyoxal, glyoxal lysine and Nε-carboxymethyllysine
(CML). Due to the different AGE-precursors, AGEs are a very
complex and heterogeneous group of compounds of which not
all structures are known yet [43]. For the partial characterization
of AGEs, a number of ﬂuorometric and colorimetric methods exist
to examine the level of protein alteration. Modiﬁcations on
arginine and lysine side chains, aggregation state of proteins,
formation of protein carbonyls, the fructosamine content as well
as autoﬂuorescence of some AGE compounds are widely used
parameters (27). Also measuring of pentosidine or CML via high-
performance liquid chromatography (HPLC) [32,35], immunoblot
and enzyme-linked immunosorbent assay (ELISA) [44], and mass
spectroscopy [33] allow the detection and provide an insight in the
structures of different AGEs. Immunohistochemistry of arterio-
sclerotic plaques showed increased intracellular AGE accumulation
in foam cells [45]. Due to various methods and protocols for
measuring and detecting AGEs, it is challenging to compare
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published results. For the effect of AGEs on cellular reactions
different ways of AGE binding and uptake have been described.
Receptors for advanced glycation end products—structure and
function
Formation of AGEs leads to the activation of different signaling
pathways mediated by a series of cell surface receptors. The most
studied AGE-receptor is the multi-ligand receptor for advanced
glycation end products (RAGE). Today several other AGE-receptors
was also identiﬁed consisting of the AGE-receptor complex
(AGE-R1/OST-48, AGE-R2/80K-H, AGE-R3/galectin-3) [46,47] and
some members of the scavenger receptor family (SR-A [48]; SR-B:
CD36 [49,50], SR-BI [51] SR-E: LOX-1 [52]; FEEL-1; FEEL-2 [53])
which are all illustrated in Fig. 3. The expression of these AGE-
receptors depends on the cell/tissue-type and is regulated in
response to metabolic changes for instances during aging, diabetes
and hyperlipidemia [54] (Table 1).
Receptor for AGEs (RAGE)
The type I cell surface receptor for AGEs (RAGE) belongs to the
immunoglobulin (Ig) superfamily and has been described as
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Table 1
Receptors for advanced glycation end products—structure and function.
AGE-binding protein Molecular weight Cell types Structural features Ligands Function
RAGE Sequence: Monocytes/Macrophages,
T-lymphocytes (CD4þ , CD8þ),
endothelial cells, mesangial
cells, ﬁbroblasts, smooth
muscle cells, neuronal cells
Highly acidic cytoplasmic domain, a single
transmembrane domain, extracellular
domain consisting of VC1-ligand binding
domain and C2 domain
S100 proteins, HMGB-1, β-amyloid, amyloid ﬁbrils,
β-integrin Mac-1, AGEs
Endocytosis, signaling (cell
activation)-generation of
ROS, inﬂammatory
response
ﬂ-RAGE: 43 kDa
sRAGE: 36 kDa
N-truncated RAGE: 32 kDa
Western Blot (WB):
ﬂ-RAGE: 55 kDa
sRAGE: 46–50 kDa
N-truncated RAGE: 42 kDa
AGE-R1/OST-48/p60 50 kDa (Sequence þWB) Monocytes/macrophages,
T-lymphocytes (CD4þ , CD8þ),
Endothelial cells, mesangial
cells, ﬁbroblasts, smooth
muscle cells, neuronal cells
Integral plasma membrane protein with a
single transmembrane domain, formation of
a complex with ribophorin I, II and DAD1 in
the RER
- Endocytic uptake and
degradation of AGE-
modiﬁed proteins,
protective against oxidative
stress
AGE-R2/80K-H/p90 Sequence: 59 kDa Monocytes/macrophages,
T-lymphocytes (CD4þ , CD8þ),
endothelial cells, mesangial
cells, ﬁbroblasts, smooth
muscle cells, neuronal cells
No transmembrane domain,
phosphorylation on tyrosine residues,
formation of a complex with PKCζ and
munc18c
AGEs Signaling (cell activation),
regulatory subunit of
glucosidase II
WB: 80 kDa
AGE-R3/galectin-3 Sequence: 26 kDa Monocytes/macrophages,
T-lymphocytes (CD4þ , CD8þ),
endothelial cells, mesangial
cells, ﬁbroblasts, smooth
muscle cells, neuronal cells
Formerly known as Mac-2 or CBP-35,
consists of a carbohydrate-binding
C-terminal domain, PGAY-rich repeating
domain, N-terminal domain, no
transmembrane domain
Cell surface: IgE receptor, colon cancer mucin,
CD66, LPS, Mac-1, Mac-3, heavy chain of CD98,
myelin-associated glycoprotein, lysosomal-
membrane-associated glycoproteins (LAMPs) 1 and
2; extracellular environment: AGEs, IgE, laminin,
tenascin, ﬁbronectin, collagen IV, gp90/Mac-2
binding protein
Signaling (cell activation)
WB: 32 kDa
SR-A (I/II) Sequence: 50 kDa (monomeric
subunit)
Monocytes/macrophages,
dendritic cells, endothelial cells
Domain I: cytoplasmic N-terminus, Domain
II: transmembrane domain, Domain III:
spacer domain, Domain IV: α-helical coiled-
coil, Domain V: collagen triple helix, Domain
VI: C-terminal domain
Endogenous ligands: AcLDL, OxLDL, AGE, β-
amyloid; Pathogen recognition: Gram-negative
bacteria (E. coli), Gram-positive bacteria (S. aureus),
bacterial DNA, LTA
Endocytic uptake and
degradation of modiﬁed
LDL and AGE-modiﬁed
proteins
WB: 77 kDa (monomer),
220 kDa (homotrimer)
SR-B/CD36 Sequence: 53 kDa Platelets, endothelial cells,
epithelial cells, adipocytes,
B-lymphocytes
Two transmembrane domains with an
extracellular loop, palmitoylated on cysteine
residues, two on each N- and C-terminus
Endogenous ligands: AcLDL, OxLDL, HDL, LDL,
VLDL, collagen, thrombospondin, long chain fatty
acids, maleylated BSA, anionic phospholipids, AGE,
apoptotic cells; Pathogen recognition: Microbial
diacylglycerides, S. aureus
Endocytic uptake and
degradation of AGEs, cell
adhesion, regulator of fatty
acid transport
WB: 88 kDa
SR-BI Sequence: 60 kDa Tissues which are active in
selective uptake of HDL (liver,
steroidogenic)
Two transmembrane domains with an
extracellular loop, palmitoylated on
C-terminal Cys462 and Cys470
AcLDL, OxLDL, LDL, HDL, VLDL, maleylated BSA,
anionic phospholipids, AGE
Selective uptake of HDL,
endocytic uptake and
degradation of AGEs
WB: 76 kDa
SR-E/LOX-1 Sequence: 31 kDa Endothelial cells, macrophages,
smooth muscle cells
Group V C-type lectin, short N-terminal
cytoplasmic domain, single transmembrane
domain, extracellular NECK domain with a
subsequent CTLD
Endogenous ligands: OxLDL, Hsp70, AGE, apoptotic
cells, activated platelets; Pathogen recognition: S.
aureus, E. coli
Endocytic uptake and
degradation of modiﬁed
oxLDL, signaling
WB: 50 kDa
FEEL-1/FEEL-2 FEEL-1: 275 kDa Endothelial cells, monocytes/
macrophages
Type I transmembrane protein, consists of
7 fasciclins, 16 EGF-like, 2 laminin-type EGF-
like and 1 link domain transmembrane
region
Endogenous ligands: AcLDL, AGE, SPARC,
hyaluronic acid; pathogen recognition: S. aureus, E.
coli
Endocytic uptake and
degradation of AGEs,
Hyaluronic acid and AcLDL
FEEL-2: 277 kDa (sequence)
190 kDa form stabilin-2
(by proteolytic cleavage): 190 kDa
(WB), 154 kDa (sequence)
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a pattern recognition receptor [55,56]. Based on molecular cloning
studies, RAGE was ﬁrst identiﬁed as a polypeptide with a mole-
cular weight of 35 kDa in bovine lung endothelial cells. According
to the protein sequence of human RAGE that consists of 404 amino
acids, the calculated molecular weight is 42.8 kDa. Western Blot
analysis of RAGE-transfected 293 cells showed major bands with a
molecular mass of 50 kDa due to post-translational processing
[55]. RAGE is expressed on several cell types (monocytes/macro-
phages [57–59], T-lymphocytes [60–62], endothelial cells [63],
dendritic cells [64,65], ﬁbroblasts [66], smooth muscle cells
[59,67], neuronal cells, glia cells, chondrocytes [68], keratinocytes
[69]) and recognizes a large number of different ligands (AGEs,
amyloid β peptide, S100/calgranulin protein, HMGB1, LPS). Ligand
binding is followed by activation of different signaling pathways
(for review see [70]). The full-length RAGE (ﬂ-RAGE) protein
consists of a large extracellular domain, a single transmembrane-
spanning helix and a short cytoplasmic domain. This intracellular
domain of ﬂ-RAGE was shown to be essential for downstream
signaling and activation of NF-κB [71]. The extracellular region is
composed of one N-terminal V-type (variable) domain and two C-
type (constant) domains [72]. The ligand-binding site is reported
to be located on the V-type domain which secondary structure
consists of two β-sheet, a short α-helix and random-coil and is
quite similar to the structure of the immunoglobulin V-type
domains [73]. In contrast to the C2-type domain, the V- and
C1-type domain act as structural unit (VC1) and form not an
independent structure. Besides, it was also shown that the VC1
domain is attached to the C2 domain by a ﬂexible linker [72].
Due to alternative splicing 20 different variants of RAGE are
known [74]. Two major splicing variants of ﬂ-RAGE mRNA are
characterized. One of these variants (N-truncated RAGE) is lacking
the N-terminal V-type domain, but is also located in the cytoplas-
mic membrane. The second splicing variant is the soluble form of
RAGE which is lacking the C-terminal domain, but contains all of
the immunoglobulin domains of ﬂ-RAGE [75]. The soluble form of
RAGE is secreted extracellularly and two different types are
identiﬁed. The ﬁrst is known as sRAGE or esRAGE and is a result
of alternative splicing of RAGE mRNA. Furthermore, ﬂ-RAGE
undergoes proteolytic cleavage through the metalloproteinase
ADAM10 and MMP9 and leads to the release of sRAGE [76]. It
was reported that sRAGE as a decoy prevents ligands to interact
with RAGE or with other cell surface receptors [77]. In patients
with coronary artery disease lower plasma levels of sRAGE were
demonstrated in an acute event suggesting an increased AGE–
RAGE interaction leading to increased production of ROS and
inﬂammatory response [74]. RAGE signaling induced by AGEs
and its physiological role will be discussed in the next sections.
The AGE-receptor complex (AGE-R)
The AGE-R complex consists of three different components and
is involved in AGE signaling and endocytotic uptake of AGE-
modiﬁed proteins. In 1991 the ﬁrst component of the AGE-R
complex was published initially as the cell surface receptor p60
in connection with AGE-modiﬁed proteins on monocytes/macro-
phages [78]. Later it was shown that p60 is homologous to OST-48,
which was identiﬁed as a 48 kDa subunit of the oligosaccharyl-
transferase complex [46,79]. OST-48 forms a complex with the two
integral membrane glycoproteins ribophorin I and II and also with
the defender against apoptotic cell death (DAD1) in the rough
endoplasmic reticulum (RER) [80–82]. It has been shown that the
homologous to OST-48, also termed AGE-R1, is an integral plasma
membrane protein with a single transmembrane segment and a
long extracellular domain, which represents the N-terminal
domain of OST-48 located luminal in the RER [46]. This identiﬁed
protein is known to be active in binding of AGE-modiﬁed proteins
on the cell surface and also as the subunit of the oligosaccharyl-
transferase complex which catalyzes the transfer of high mannose
oligosaccharides onto asparagine-acceptor sites of proteins inside
the RER [46,79]. AGEs induce an enhanced expression of AGE-R1/
OST-48, which activation suppresses RAGE, prevent the generation
of cellular oxidative stress and also blocks the activation of the
oxidative stress dependent signaling of the EGF-receptor [83–85].
Vlassara et al. have also shown that the AGE-R1/OST-48 level in
PBMCs positively correlates with plasma and urine AGEs as well as
with oxidative stress markers in healthy participants and nega-
tively in patients with stage 3 chronic kidney disease (CKD-3) [86].
These data support the hypothesis that AGE-R1/OST-48 has a
protective role against the formation of ROS, oxidative stress
dependent cell damage and tissue injury.
Similar to the AGE-R1/OST-48, the second component of the
AGE-R complex was known ﬁrst as 80K-H protein, which is an
effective phosphorylation substrate for the protein kinase C (PKC).
This acidic 80 kDa protein was ﬁrst puriﬁed from the human
carcinoma Ca9-22 cell line and is located in the cytosol and
membrane with no apparent transmembrane domain [87,88].
A few years later it was shown that 80K-H is identical to the
AGE-binding protein p90, which was identiﬁed as speciﬁc cell
surface binding protein on the membrane of murine macrophage
cell line RAW 264.7 for the AGE 2-(2-furoyl)-4(5)-(2-furanyl)-1H-
imidazole [46,89,90]. The biological function of AGE-R2/80K-H is
poorly understood. It was demonstrated that phosphorylation of
this protein occurs on tyrosine residues and it is involved in the
intracellular receptor signaling, like FGF receptor signaling
[90–92]. The AGE-R2/80K-H protein is also linked to intracellular
trafﬁcking in connection with AGEs and it is closely related to
VASAP-60, which is a regulator of vesicle trafﬁcking [46,93].
Furthermore, it was suggested that the 80K-H phosphoprotein
was an interactor with both, the PKCζ and munc18c and plays a
role in the GLUT4 vesicle trafﬁcking pathway, whereby insulin
triggers the formation of a PKCζ–80K-H–munc18c complex which
leads to an enhanced glucose transport through GLUT4 [94].
The third component of the AGE-R complex is a member of the
lectin family. It was ﬁrst described on the cell surface of activated
macrophages with a size of 32 kDa and termed Mac-2 [95] This
protein has been rediscovered in different species (human, dog, rat
and mouse tissues) and also in different contexts, leading to
multiple names like Mac-2, CBP-35, CBP-30 and L-29 [96]. Thus,
a generally accepted nomenclature was established and this
protein was named galectin-3 [97]. In 1995, galectin-3 was
identiﬁed as a part of the AGE-R complex with a high binding
afﬁnity of AGE ligands [47]. AGE-R3/galectin-3 consists of a
carbohydrate-binding C-terminal domain composed of 130 amino
acid residues, a proline–glycine–alanine–tyrosine-rich repeating
domain (100 residues) and a short N-terminal domain (30
residues) [96]. AGE-binding occurs also in the C-terminal carbohy-
drate recognition domain and promotes the formation of a high
molecular weight complex with other receptor molecules and the
AGE ligands [47,91]. The lack of a transmembrane domain sup-
ports the assumption that this protein is located on the cell surface
linked to other AGE receptor molecules [47]. The AGE-R3/galectin-
3 protein is mainly located in the cytoplasma, but was also found
in the nucleus, on the cell surface and the extracellular environ-
ment. It has been shown that the endogenous lectin is predomi-
nantly phosphorylated on the N-terminal Ser6 residue and the
phosphorylated form could be detected also in the cytoplasm and
the nucleus of 3T3 ﬁbroblasts and colon cancer cells [98–100].
The phosphorylation affected the ligand binding signiﬁcantly and
leads to a reduced saturation binding greater than 85% which was
tested with the two galectin-3 ligands laminin and mucin. Depho-
sphorylation can completely restore the ligand binding activity
and suggests that phosphorylation on Ser6 works as an “on/off”
C. Ott et al. / Redox Biology 2 (2014) 411–429416
switch for its sugar binding capabilities and seems to be important
for the understanding of the biological function of the AGE-R3/
galectin-3 protein [100]. However, it remains unknown if the
extracellular AGE-R3/galectin-3 can also be phosphorylated and
if this affects the extracellular binding of AGE-modiﬁed proteins as
well. Upregulation of AGE-R3/galectin-3 leads to an increased
metastatic potential in cancer. Phosphorylation of AGE-R3/galec-
tin-3 regulates the anti-apoptotic signaling activity resulting to an
enhanced metastatic potential [101]. Furthermore, the biological
function of the AGE-R3/galectin-3 protein has been implicated also
in the processes of cell migration and adhesion, immune response
modulation, growth and differentiation [47,96,102] and in addition
it has been shown that AGE-R3/galectin-3 and RAGE participates
in vascular osteogenesis by modulating Wnt/β-catenin signaling
with the two receptors showing diverging effects on VSMC
osteogenic differentiation [103]. This assists in understanding the
mechanism of the development of atherosclerosis and the role of
the AGE receptors in this process.
Macrophage scavenger receptor family
The scavenger receptor family describes a group of receptors
with a common afﬁnity to recognize modiﬁed proteins like oxidized
low-density lipoprotein (OxLDL) or acetylated LDL (AcLDL). The
scavenger receptor was ﬁrst discovered in 1979 by Goldstein and
Brown. They demonstrated a high afﬁnity binding site on mouse
peritoneal macrophages that recognizes AcLDL but not native LDL.
In addition to AcLDL also other negatively charged ligands including
maleyl-LDL, malelyl-BSA and sulfated polysaccharides were shown
to bind this receptor [104]. One contemporary problem at that time
was the physiological relevance because the uptake of AcLDL
occurred in vitro and was not known in vivo. Two years later it
was shown that native human LDL incubated with rabbit aortic
endothelial cells was modiﬁed into a form of LDL that was also
recognized by the macrophage receptor for AcLDL [105]. The
generation of this modiﬁed LDL molecules can occur in the absence
of cells using a medium containing redox metals, such as copper
[106] and/or by free SH-groups [107,108]; in the presence of smooth
muscle cells, endothelial cells and macrophages themselves [108]
and it could be proved that oxidation of LDL also occurs in vivo
[109]. The deﬁnition of this type of receptors as scavenger receptors
is due to the initial described function to mediate the uptake and
degradation of modiﬁed proteins. Today, a large number of different
scavenger receptors have been identiﬁed and are classiﬁed accord-
ing to their structural properties (Fig. 3).
The scavenger receptor class A (SR-A) are trimeric transmem-
brane glycoproteins with a relative molecular weight of 220 kDa
(monomeric subunit: 77 kDa) and consist of ﬁve (SR-AII) or six
(SR-AI) different domains. The N-terminal cytoplasmic domain
contains 50 amino acids, followed by a 25-amino acid transmem-
brane spanning domain; a 75-amino acid spacer region; a
121-amino acid α-helical coiled coil motif, a 69-amino acid
collagen-like triple helix and the C-terminal domain [110]. The C-
terminal domain of the SR-AI receptor contains a cysteine-rich
motif which is absent in the SR-AII receptor [111]. The ligand
binding occurs at the collagenous domain and leads to the endo-
cytic uptake of OxLDL or AcLDL and further to the intracellular
accumulation of cholesterol and the formation of foam cells from
macrophages in the early state of atherosclerosis [112]. The SR-A
was also described as AGE-binding receptor, mediating the endo-
cytotic uptake and degradation of AGE-modiﬁed proteins in com-
petition to modiﬁed LDL [48]. Due to the fact that foam cells are
formed from macrophages and the SR-A are the mainly expressed
receptors on these cells, the AGE-binding on these receptors could
play a crucial role in the development of atherosclerosis.
Two other receptors, CD36 and SR-BI, belong to the scavenger
receptor class B (SR-B) and are concentrated in caveolae-like
domains on the cell surface. Both receptors are glycoproteins with
two transmembrane domains, a large extracellular loop and short
N- and C-terminal domains with a signiﬁcant sequence homology
in the extracellular domain [113]. However, this sequence homol-
ogy between the two receptors is not present in the N- and
C-terminus. It was also shown that CD36 and SR-BI are fatty-
acylated. In the human CD36 four cysteine residues could be
identiﬁed as major site of palmitoylation, two at both the
N-terminal and C-terminal domain [114]. Studies on murine SR-BI
indicates a potential site of palmitoylation at Cys462 and Cys470
which are located in the C-terminus [115]. In CHO cells over-
expressing human CD36 or hamster SR-BI a speciﬁc cell association
to AGE-modiﬁed BSA was reported, leading to endocytic uptake of
AGEs and identiﬁed CD36 and SR-BI as AGE-receptors [49,51]. As
shown in murine SR-BI-transfected ldlA cells (LDL receptor-negative
CHO cells) SR-BI recognizes HDL and mediates selective transfer
from HDL to cells without endocytic uptake of HDL [116]. Binding of
AGE ligands to SR-BI can inhibit the selective HDL uptake and
involves AGEs in the regulation of the SR-BI mediated cholesterol
metabolism [51]. Related to the SR-A receptors, CD36 is as well
highly expressed on macrophages in atherosclerotic lesions and
recognizes OxLDL as ligand. Nakata et al. detected CD36 mainly in
the core region of an atherosclerotic plaque by immunohistochem-
ical staining, whereas SR-A is mainly localized around the core
region which suggests different functions of both CD36 and SR-A in
the process of atherogenesis [117]. CD36 was also described as AGE-
receptor on mouse 3T3-L1 cells and human subcutaneous adipo-
cytes which recognized AGE-BSA modiﬁed by glycolaldehyde (GA)
and methylglyoxal (MG) undergoing endocytic degradation [118].
Incubation of these cells with GA-BSA induces intracellular oxida-
tive stress and leads to leptin downregulation which is related to
exacerbation of insulin sensitivity in vivo [119]. This indicates a
pathological role of CD36 as AGE-receptor in diabetic complications
and atherogenesis.
Furthermore, some other members of the scavenger receptor
family were reported to bind AGEs. One of them is the lectin-like
oxidized LDL receptor-1 (LOX-1). This receptor was identiﬁed in
endothelial cells as a receptor for OxLDL and has a molecular
weight of 50 kDa [120]. LOX-1 is a type II transmembrane
glycoprotein and belongs to the group V C-type lectins [121]. It
is expressed with a short N-terminal cytoplasmic domain, a single
transmembrane domain and a stalk region (NECK domain) with a
subsequent C-terminal lectin-like domain (CTLD) in the extracel-
lular region. The CTLD of the human LOX-1 has an inter-chain
disulﬁde bridge at Cys140 to form the homodimeric ligand-binding
domain and the NECK domain as a homodimer consists of two α-
helices that wrap in a left-handed helix to build a coiled coil [122].
LOX-1 is localized mainly in vascular tissues and is highly
expressed in patients or animals with atherosclerosis or diabetic
complications. It is reported that NF-κB is a downstream signal of
LOX-1 and its expression is affected by testosterone that can
regulate the atherosclerotic plaque progression in the rabbit
thoracic aorta [123]. In addition to OxLDL, LOX-1 also binds
MG- or GA-modiﬁed BSA. Cross-competition experiments show
that the binding of OxLDL or AGE-BSA was not affected by the
other ligands. Similar results have been obtained with HDL or
AGE-BSA binding on SR-BI in CHO cells overexpressing SR-BI. A
possible reason for these results might be the presence of multiple
ligand binding sites in both receptors, LOX-1 and SR-BI. In these
studies it was also shown that in contrast to the receptor LOX-1
which mediates the endocytic uptake and degradation of OxLDL
but not of AGE-BSA, the SR-BI receptor mediates the endocytic
uptake of AGE-modiﬁed proteins but not of HDL [52]. Further
studies indicate that AGE-BSA induces LOX-1 expression in
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endothelial cells in vitro that is not mediated by activation of NF-κB
but rather through RAGE-mediated activation of the mTOR pathway
[124]. Due to the fact that mTOR plays a role in cardiovascular-related
disorders, the induced LOX-1 expression by AGEs may also contribute
to diabetic complications such as atherosclerosis [124,125].
Fasciclin, EGF-like-, laminin-type EGF-like, and link domain-
containing scavenger receptor-1 (FEEL-1) and FEEL-2 was cloned
from human umbilical vein endothelial cells and ﬁrst reported as a
receptor for AcLDL [126]. FEEL-2 is a paralogous protein of FEEL-1
(2570 amino acids) with a sequence homology of 39.8%. Both
receptors are type I transmembrane proteins and are composed of
seven fasciclins, 16 EGF-like, two laminin-type EGF-like and one
link domain near the transmembrane region [53,126]. First, FEEL-
1/FEEL-2 were known as stabilin-1 and stabilin-2, and additionally
FEEL-1 was also identiﬁed as the common lymphatic endothelial
and vascular endothelial receptor-1 (CLEVER-1) [127,128]. In CHO
cells overexpressing FEEL-1 or FEEL-2 an endocytic uptake and
degradation of AGE-BSA was shown. The AGE-binding by FEEL-1/
FEEL-2 was competed with other ligands like AcLDL or OxLDL
suggesting the same binding site on the receptors [53]. It was also
shown that AGE-BSA is endocytosed by choriocapillaris endothe-
lial cells located in Bruch0s membrane via a FEEL-1/FEEL-2
mediated pathway [129].
Receptor trafﬁcking and intracellular proteolysis of AGEs
Whether AGEs are originating from exogenous or endogenous
sources these compounds have to be removed to prevent addi-
tional protein modiﬁcations and protein cross-linking. Prior to the
disposal of AGEs they have to be further processed to be elimi-
nated by the renal systems. Thereby, the degradation of AGEs
occurs intracellular, meaning that they ﬁrst need to be taken up by
the cells. Processing of AGE-modiﬁed proteins into AGE-modiﬁed
peptides makes them eliminable for the renal system. As already
mentioned, some of the AGE-receptors are able to bind AGEs
for subsequent intracellular processing. AGE-receptors which are
believed to be involved in detoxiﬁcation are the AGE-R1/OST-48,
AGE-R3/galectin-3 as well as scavenger-receptors (MSR-AII,
MSR-BI, CD36) [48,50,130]. There exist strong evidence that under
basal conditions AGE-R1/OST-48 and AGE-R3/galectin-3 have a
high afﬁnity to bind AGEs [131]. Cells constantly express a majority
of cell surface receptors to internalize signaling molecules leading
to an activation of speciﬁc intracellular signaling cascades in
response to changes of the extracellular environment. Thereby, it
is assumed that they inhibit the AGE-mediated signaling and
oxidative stress by competing with RAGE to AGEs. Uptake of AGEs
by AGE- and scavenger receptors is described through receptor-
mediated endocytosis [48,132,133]. Ligand-binding activates the
receptor through phosphorylation or ubiquitinylation of the cyto-
plasmic side of the receptor stimulating the receptor endocytosis.
The internalization of the ligand-receptor complex undergoes a
regulated mechanism that is either clathrin-dependent or -inde-
pendent. The best-studied mechanism is the clathrin-mediated
endocytosis through clathrin-coated vesicles. These vesicles are
transported to early endosomes and undergo a not yet well-
understood series of endosomal sorting processes. Inside the
newly formed endosomes AGEs are dissociated from the receptor,
triggered by a decrease of pH within the endosomes (for review
see [134–136]). After separating the receptor can be recycled and
transferred back to the cell surface. In case of RAGE, it was
reported that in endothelial cells the receptor can be rapidly
transferred back from intracellular storage pools to the plasma
membrane [137]. Meanwhile endosomes with AGEs fuse with
lysosomes, following by processing of AGEs by lysosomal pro-
teases. Grimm et al. demonstrated that lysosomal proteases, such
as cathepsins D, L and B play a crucial role in AGE disposal
[138,139]. After processing, small soluble AGE modiﬁed peptides
are probably released by unknown mechanisms from the cells and
transported to the renal system by processes which are not known
yet. Impaired function of the kidney would result in accumulation
of AGEs. In addition Sano et al. demonstrated that insulin can also
lead to AGE elimination over enhanced uptake via macrophage
scavenger receptors. Thereby, it comes to an activation of the
phosphatidyl-inositol-3-OH kinase (PI3) pathway, following by
increase in nitric oxide and insulin-mediated glucose transport
in skeletal muscles and adipocytes [140]. Sevillano et al. have
reported the internalization of RAGE after AGE binding and its
necessity for the generation of intracellular responses [141].
AGE-mediated signaling via RAGE
As mentioned above, AGEs can be formed exo- and endogen-
ously and afterwards inﬂuence cellular metabolism. The main
sources of exogenous AGEs are heat-treated protein rich foods
containing lipids and/or sugar and compounds formed during
smoking of cigarettes [142]. Even though several studies were
already able to show an increase of plasma-AGE-levels after intake
of AGE-rich food, the intestinal uptake of AGEs as well as the
intake in lung alveoli play only a minor role [143–145]. Never-
theless, exogenous AGEs were shown to have pro-inﬂammatory
and pro-oxidant effects and that a dietary restriction of AGE-rich
food was associated with signiﬁcantly reduced inﬂammation [143]
and protein modiﬁcations [146–148]. How and to which amount
dietary AGEs are taken up is not known yet. Geissler et al. detected
that peptide-transporter PEPT1 is possibly able to absorb pyrallin
[149]. Furthermore, Forster et al. have demonstrated in a study
that after intake of pentosidine- and pyrraline-rich food, approxi-
mately 50% of the AGE were measurable in the urine until the
third day after consumption [150]. As mentioned in the previous
section, many different receptors are discussed to play a crucial
role in the cellular uptake or effects of AGEs. Thereby, RAGE is
currently the best studied. It is assumed that the AGE–RAGE
interactions play a major role in many signaling pathways
(Table 2). In the following section some of them as well as the
elimination of AGEs will be described.
AGE–RAGE interaction in oxidative and nitrosative stress:
a vicious circle
As described above, AGE formation depends on the concentra-
tion and reactivity of glucose, amount of AGE-precursors and the
availability of free amino groups. AGE formation is facilitated by
ROS. Furthermore, the effect of reactive nitrogen species (RNS) on
AGE formation has also been investigated. Reactive nitrogen
species are reaction products of nitric oxide (NOd) produced by
nitric oxide synthase (NOS) and superoxide anion (O2d), pro-
duced by NAPDH-oxidases [7,151]. While NOS is inducible by
cytokines (iNOS) [152], NADPH-oxidase can be activated through
AGE–RAGE interactions. The increase of NOd and O2d promotes
the formation of peroxynitrite (ONOO), a nitrating and oxidizing
agent, leading to inactivation of functional proteins. Furthermore,
the increase of ROS leads to an activation of transcription factor
nuclear factor kappa-light-chain-enhancer of activated B (Nf-κB),
resulting in upregulation of iNOS [153] and additional induction of
nitrosative stress and the formation of elevated levels of perox-
ynitrite [154]. Summarizing, an AGE–RAGE interaction promotes
NADPH-oxidase activity, resulting in activation of Nf-κB, followed
by expression of iNOS and increased formation of ONOO .
Additionally, Liu et al. determined that RAGE is involved in
nitrotyrosine production [155]. The authors were able to show a
possible link between activation of RAGE by AGEs and an increase
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Table 2
Effect of advanced glycation end products on intracellular signaling.
AGE-precursor/AGE Cell line Pathways/activated transcription factors Effective concentrations Outcome Ref.
BSA–AGE (glucose,
ribose, fructose,
methylglyoxal,
glyoxal)
Murine RAW-cells AGE–RAGE mediated Jak–Stat-pathway Glyoxal/MG-BSA: 10 mM/mg BSA,
fructose-, glucose, ribose-BSA:
25 mM/mg BSA
-Increased expression of immunoproteasomal subunits (LMP7, LMP2, MECL-1) [30]
Phosphorylation: Jak-2, Stat-1 -Decreased expression of proteasome subunits (β1, β2, β5)
-Expression of MHC-1 complexes
CML-BSA, AGE-BSA,
human-serum-AGE
(HsA)
Rat mesanglia cells Angiotensin II-TGFβ-SMAD signaling AGE-BSA: 10–100 mg/ml -Increase of Angiotensin II induced TGFβ signaling [220]
Angiotensin II, TGF-β, Smad2, p27Kip1 CML-BSA: 10–50 mg/ml -Smad2 phosphorylation
HsA: 500 mg/ml -Upregulation of cyclin-dependent kinase inhibitor 1B (p27Kip1) leading to cell
hypertrophy and increased ﬁbronectin
-increased RAGE expression
- ROS generation by interaction with RAGE
CML-collagen Dermal ﬁbroblasts Induction of apoptosis via FOXO1 200 mg/ml -Activation of caspase-3-activity and apoptosis via induction of ROS, ceramide and
NO, leading to activation MAPK p38 and JNK pathways and FOXO1 followed by TNF-
mediated pro-apoptotic gene expression
[221]
p38 and JNK, FOXO1, TNFs
BSA–AGE
(methylglyoxal)
Bovine retinal
pericytes
Induction of apoptosis via diaglycerol (DAG)
and ceramides
3 mM (1–20 mM) -Phosphatidylcholine-speciﬁc phospholipase C mediated DAG production [222]
-Activation acidic sphingomyelinase, producing ceramides-apoptose
BSA–AGE (glucose) Rat vascular
smooth muscle
cells (A7R5)
Induction of autophagy via Akt-mTOR 100 mg/ml -AGE–RAGE interaction increased autophagy via ERK [223]
Phosphorylation of ERK, MAPK p38, JNK Inhibited
phosphorylation Akt
-Increased autophagic vacuoles
-Increased LC3-II to LC3-I ratio
-Increased proliferation of VSMCs
-Activation of Akt via IGF-1 decreased AGE-mediated autophagy
BSA–AGE Human
chondrocyte from
osteoarthritis
patients
Augment inﬂammatory responses Up to 800 mg/ml -AGE–RAGE mediated activation of PGE2 and NO via MAPKs, NF-κB [224]
COX-2, COX-1, mPGES-1 and INOS, JNK, MAPK p38, ERK, NF-κB -COX-2, COX-1, mPGES-1, INOS expression
BSA–AGE (glucose) Human aortic
smooth muscle
cells
Calciﬁcation of vascular smooth muscle cells
Phosphorylation of MAPK 38
1–100 mg/ml -Activation of alkaline phosphatase promote mineralization and vascular
calciﬁcation
[162]
-Calciﬁcation is due to AGE–RAGE activated p38 MAPK pathway
BSA–AGE (glucose) Rat vascular
smooth muscle cell
AGE-mediated activation of inducible nitric oxidase (iNOS) 1–500 mg/ml -AGE-mediated induction of ROS via NADPH oxidase [154]
NF-κB, Nox1 -Upregulation of NF-κB followed by increased expression of iNOS via Nox1 leading
to induced superoxide production
-Induced nitrotyrosin formation
BSA–AGE Murine mesangial
cells
AGE turnover via AGE-recptor 1 100 mg/ml -Increased AGE turnover and reduction of NF-κB in AGE-R1 overexpressing
mesangial cells
[83]
MAPK p42/44, NF-κB -Suppressed RAGE-signaling and MCP-1 synthesis by AGE-R1
-silencing AGE-R1 led to enhanced p44/42 phosphorylation
BSA–AGE Rat heart myoblast
cell line H9c2
MEK-ERK pathway 50–200 mg/ml -Increased ROS production [225]
Phosphorylation MEK, ERK, JNK, Akt -Increase cell size and total protein
-AGE meditated cell hypertrophy via MEK/ERK pathway
Glycerol-, glycol-AGE Human endothelia
cells
Angiogenesis 100 mg/ml -Increased expression vascular endothelial growth factor (VEGF) and angiopoietin-2 [226]
-Activation of NF-κB and activation protein-1 (AP-1)
AGE Rat cardiac
myoﬁbroblasts
H9C2
Upregulation of inﬂammatory cytokines 100 mg/ml -Increase ROS production and RAGE and NOX-p47 phox protein expression [227]
-Increased cytokine expression: iNOS, TNF-α, TGF-β
-Inhibition of cytokine expression with gallic acid
BSA–AGE (glucose,
ribose)
Rat pulmonary
artery smooth
muscle cells
p21ras-dependent mitogen-activated
protein kinase pathway
Up to 100 mg/ml -Activation of endogenous p21ras via AGE–RAGE interaction, ERK1/2 and NF-κB [228]
-Inhibition of p21ras blocked activation of NF-κB
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of nitrated thioredoxin in mice after diabetic myocardial ischemia–
reperfusion (MI/R) injury. They have shown that increased RAGE
levels led to the inactivation of thioredoxin by an increased
nitration, followed by its loss in anti-apoptotic, anti-oxidative
function and its functionality in cardiac protection. While RAGE
modulates the nitration of thioredoxin through induced peroxyni-
trite generation, reduced non-nitrated thioredoxin inhibits RAGE
expression, suggesting a cross-talk between both [155]. Further-
more, Nagai et al. showed that RNS are involved in AGE generation
[156]. The incubation of glycated human serum albumin (HsA)
with peroxynitrite results in an increase of CML formation.
Glucose and peroxynitrite were shown to react to glucosone and
glyoxal, which further promote CML generation [145]. Summariz-
ing, the cross-talk between AGEs and nitrosative stress is mainly
due to the amount of reactive oxygen and nitrogen species as well
as the antioxidant property of the cells. An imbalance between
antioxidative enzymes and ROS-meditated AGE production pro-
motes the development of further ROS and RNS, such as perox-
ynitrite and leads to a vicious cycle of nitrosative stress and further
protein damage.
AGE–RAGE-mediated signaling via Janus kinase (Jak) signal
transducers and activators of transcription (Stat)
Jak/Stat pathway activation can be driven by various substances
and are connected to many different pathways. Today, four Jaks
(TYK2, Jak-1, Jak-2, and Jak-3) and seven Stats (Stat-1, -2, -3, -4,
-5a, -5b and -6) are known. Interferon γ (INF-γ) is an excellent
example for triggering the signaling cascade of Jak/Stat. Binding of
INF-γ to its cell-surface receptor INF-γR activates the receptor-
associated Janus kinase 1 (Jak-1) und Jak-2 via phosphorylation,
followed by the activation of Stat-1 via phosphorylation of its
tyrosin residue 701 [30,157]. After activation two Stat-1 molecules
dimerize and further translocate together with interferon regula-
tory factor 1 (IRF-1) into the nucleus. There, the complex binds on
interferon stimulated response element (ISRE) sequences, indu-
cing cytokine production, such as INF-γ and an increased expres-
sion of the immunoform of the proteasom (Fig. 4) [145]. Grimm
et al. have shown a similar mechanism for AGE-mediated Jak–Stat
activation. After treatment of macrophages with different AGE-
precursors for 72 h they observed an increase in Jak-2 and Stat-1
phosphorylation. Furthermore, they demonstrated an increased
expression of immunoproteasomal subunits. Inhibition of Stat-1
and Jak-2 reduced AGE induced expression of proteolytic subunits
of the immunoproteasome. Silencing of RAGE conﬁrmed that the
receptor is involved in AGE mediated induction of immunopro-
teasomal subunits. Thus, AGEs are able to activate Jak-2 and Stat-1
via RAGE and thereby affect the composition and activity of
proteasomal subunits [30]. Besides the regulation of the protea-
some, AGEs are also involved in the reduction of collagen
type II and chondrial cartilage via Jak–Stat signaling. Therefore,
AGE–RAGE interaction activates Jak-2/Jak-3 resulting in activation of
Stat-3 and the expression of matrix-metallopeptidase 13 (MMP-13,
collagen III) and ADAMST 4/5 (cleavage of proteoglycan aggrecan).
At high levels both enzymes are responsible for rapid degradation
of collagen type II, resulting in osteoarthritis. Inhibition of Stat-3
Nucleus
extracellular
intracellular
Stat1
Stat1
Stat1
Jak 1
P
IRP1
Stat1 Stat1
11Sαβ
NADPH
Oxidase
R
A
G
E
NFκB
p65/p50
p52
p21Ras
Cytokines,
growth
factors
ROS
NFκB
Stat3
IRP1
P
Proteins
Lysosomal
degradation
of AGEs via
cathepsins
Endosome
+ receptor-
bound AGE
Separation
AGEs and
receptor
N
H
H Collagen
Hemoglobin
Glc
Further protein
modifications/cross-linking
Fusion
endosome &
lysosome
+
Renal
elimination/
clearance
AGE 
peptides
AGE-MEDIATED
SIGNALING
AGE-protein
Cross-links
PROCESSING
OF AGEs
Endo-
genous
AGEs
RAF-1
Exo-
genous
AGEs
Glc
Glc
P
P
P P
V
C1
C2
ERK
MEK1/2
MEKK1
MAPK
p38
JNK
Jak 2
P P
V
C1
C2
IRSE
Receptor-mediated
endocytose
C
D
36
Receptor
recyclingMEK3/6
Fig. 4. AGE-mediated signaling and detoxiﬁcation of AGEs via lysosomal system. AGE–RAGE interaction stimulates a various number of signaling cascades, including Jak/Stat,
NADPH oxidase, mitogen activated protein kinasen (MAPK), such as p38, extracellular regulated (ERK)-1/2 and c-Jun N-terminal kinase (JNK). AGE-mediated signaling via
RAGE leads to the activation of transcription factors, such as nuclear factor (NF-kB) or IFN-stimulated response elements (ISRE) followed by an increased expression of
cytokines, growth factors or i.e., immunoproteasomal subunits. While RAGE–AGE interactions are believed to activate inﬂammatory pathways, other receptors i.e., the family
of scavenger receptors play an important role in receptor-mediated endocytosis, leading to intracellular uptake and (parial) degradation of AGEs by fusion with lysosomes.
Furthermore, AGE peptides can be transferred to the renal system, while the receptors will be recycled and available for endocytosis processes (modiﬁed from
[30,54,83,86,139,215]).
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shows a reduction of AGE-induced loss of collagen II [158]. In
contrast, Huang et al. showed an AGE-mediated increase of collagen
IV production in rat kidney ﬁbroblasts via Jak-2/Stat-1/Stat-3
activity. Due to mutations and increasing levels of collagen IV,
the glomerular membrane gets thinner until it dissolves [159–161].
This shows that the impact of the modiﬁcation on collagen is type
and tissue speciﬁc. In conclusion, AGE–RAGE interaction can reg-
ulate different transcription factors via activation of Jak/Stat signal-
ing. Some of them were shown to block by inhibition of Jak/Stat
activity as well as RAGE inhibition [30,159].
AGE–RAGE interaction during vascular calciﬁcation and ossiﬁcation
During the aging process, vascular calciﬁcation is a common
feature in vessel walls. It correlates with plaque instability and
inﬂammation during atherogenesis. Due to the response on
inﬂammatory stimuli, vascular cells produce matrix vesicles in
which calcium precipitates and forms calciﬁed nuclei. Subse-
quently, the induction of necrosis and apoptosis and the activation
of matrix degrading processes, results in plaque rupture [8]. Thus,
vascular calciﬁcation ends in a decrease of elasticity and stability
of the vessel walls. In diabetes mellitus arterial calciﬁcation is
often associated with an elevated level of mortality, morbidity and
stroke. Due to the fact that AGEs can cause inﬂammation, they
have the ability to promote vascular calciﬁcation. Moreover, Wei
et al. demonstrated that AGEs increase vascular calciﬁcation by
inducing osteoblast-like differentiation via RAGE pathway [7].
They investigated elevated levels of aorta AGEs, RAGE expression
and arterial calciﬁcation. Furthermore, they have demonstrated
that an inhibition of RAGE by an anti-RAGE blocking antibody
is able to reduce calciﬁcation in rat vascular smooth muscle
cells [162], suggesting that the AGE–RAGE–ROS pathway plays an
important role in vascular calciﬁcation [7] and bone metabolism
[146–148]. In contrast, Li et al. showed that RAGE expression
impaired osteoblast proliferation. They demonstrated that the
negative regulation of RAGE goes back to the repression of the
Wnt, phosphoinositol 3 kinase (PI3K) and extracellular-signal
regulated kinase (ERK) pathway. Wnt/β-catenin signaling is known
for regulating osteoblast proliferation and differentiation, leading
to bone mass formation. An overexpression of RAGE was shown to
reduce the expression of Wnt-related genes, which control cell
proliferation. In contrast to vascular calciﬁcation, RAGE is also
associated with bone loss-associated diseases [163].
Cross-talk of RAGE, AGE-R1, AGE-R3/galectin3
As mentioned in the section above, RAGE plays an important
role in AGE-mediated signaling, inﬂammatory response and ROS-
related NF-κB activation. In contrast, AGE-R1 and AGE-R3/galec-
tin3 showed opposite effects. Moreover, several studies describe a
negative regulation of RAGE via the other AGE-receptors
[83,86,103,164,165]. Cai et al. demonstrated that AGE-R1 reduced
pro-inﬂammatory response by suppressing phosphorylation of
protein p66Shc. P66Shc signaling pathway is induced by AGE-
mediated ROS and regulated via epidermal growth factor receptor
(EGFR), mitogen-activated protein/ERK kinase kinases (MEKK) and
ERK, leading to inactivation of forkhead transcription factor
(FKHRL1) and impaired manganese superoxide dismutase
(MnSOD) activity. Cells overexpressing AGE-R1 were resistant
against oxidative damage and cell injury, suggesting that AGE-R1
controls inﬂammatory signals by inhibiting p66Shc signaling.
Hence it was demonstrated that the pathway can be blocked by
AGE-R1 which represents an alternative path against AGE-induced
ROS formation [85]. Additionally, increased expression of AGE-R1
impaired AGE-induced NF-κB activity and MAPK1/2 phosphoryla-
tion and lead to an elevated degradation of AGEs [84]. Accordingly,
Lu et al. investigated the involvement of RAGE in downregulation
of NF-κB activity. They demonstrated that AGE-induced ROS
formation activates MAPK/p42/44 and NF-κB, resulting in
enhanced expression of RAGE. In a model with overexpressed
AGE-R1 they have shown a higher binding of AGEs by AGE-R1,
resulting in decreased RAGE activity and intracellular AGE-
mediated signaling. Inhibition of AGE-R1 by siRNA leads to an
elevated activity of MAPK/p44/42. Besides AGE-R1 the interaction
of AGE-R3/galectin3 has also been studied. AGE-R3/galectin3
belongs to the lactose-binding lectin families as component of
80K-H [166]. As an AGE-receptor, it is directly involved in the
modulation of Wnt/β-catenin signaling, responsible for osteogenic
differentiation [167].
Although AGE-R1 and AGE-R3/galectin3 have the ability to
reduce AGE-mediated ROS and RAGE activity, their expression and
function decreases during aging and under higher levels of
oxidative stress. Besides the antioxidative enzymes, the activity
of AGE-R1 and AGE-R3/galectin3 is also impaired. It was demon-
strated that accumulation of AGEs/ALEs and the reduced function
of AGE-R3/galectin3 promote dysregulation of vascular calciﬁca-
tion induced by AGE–RAGE interaction. Cai et al. conclude that
decreasing AGE-R1 during diabetes and aging reduced the anti-
oxidant defense and led to increasing levels of oxidative stress
[85]. Besides the downregulation of AGE-R1, NADþ-dependent
deacetylase and survival factor 1 (SIRT1) levels were also
decreased under elevated state of oxidative stress. SIRT1 is
furthermore responsible for repression of inﬂammatory signals
and insulin efﬁciency. Increased ROS via AGE–RAGE interaction
can cause the decrease in AGE-R1 and SIRT1, leading to increased
inﬂammation processes and impaired insulin-signaling pathways
[165]. Due to the fact that elevated ROS levels already play an
important role in the young generation, the decrease of AGE-R1
and SIRT1 is not only limited to the aging population. Levels of
AGE-R1 depend mainly on circulating AGEs, AGE metabolism, state
of oxidative stress and elimination via kidney. Elevated dietary
intake of AGEs can promote the abnormal ROS formation, followed
by a decrease expression and function of AGE-R1, AGE-R3/galec-
tin3 and SIRT1, resulting in an increasing development of chronic
diseases [86].
In summary, it has been shown that AGEs inﬂuence many
different signaling pathways. Thereby, reactive oxygen and nitro-
gen species as well as the intake of glucose and dietary AGEs play
an important role in the formation of endogenous AGEs. The
prevention of AGE formation by reducing dietary glucose intake,
inhibiting cellular AGE–RAGE interaction and promoting AGE
clearance may provide primary approaches against increasing
AGE-levels [168].
Physiological role of RAGE
The question of the functional relevance of RAGE has become
more and more popular. Besides the potential role of RAGE in
embryogenesis and aging, the physiological function is largely
undeﬁned. As RAGE is highly expressed in the lung, the lung is a
desired organ for investigation. Thus, most data exist from lung,
followed by its role in the immune system and less is known about
its involvement in bone metabolism or neuronal processes (Fig. 5).
RAGE expression: from fetal to adult
The ﬁrst detectable RAGE mRNA-expression goes back to the
early blastocyst stage at day 4 in the rabbit embryo. The expression
increases in the gastrulating blastocyst on day 6 (stage 0–2,
Fig. 6A). During the blastocyst formation RAGE expression is
mainly localized in the embryoblast and barely in trophoblast
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cells (Fig. 6B). Immunohistochemical staining reveals a dominant
staining of the membrane. The role of RAGE in the early blastocyst
is unclear. In the human Konishi et al. conﬁrmed the presence of
RAGE in trophoblast cell in chorionic villi of the ﬁrst trimester, but
just with its association to induce oxidative stress [169]. There are
barely data about RAGE during embryogenesis in the literature.
Reynolds et al. described RAGE expression in endothelial cells
of embryonic vessels and alveolar capillaries in the rat [170].
Hori et al. found RAGE mRNA and protein expression in (E17)
embryonic cortical neurons from rats and, for the ﬁrst time, with a
functional relevance for neurite outgrowth [171]. However, most
data dealing with RAGE during embryogenesis suggest RAGE to be
crucial for organogenesis of the lung. Western blot analysis
revealed a steady increase in RAGE expression from fetal (E19),
term, 4 day, 8 day to adult lungs in rats [172], with 2-fold increase
of mRAGE expression in the adult lung compared to the neonate.
This gradual increase of RAGE from fetal to birth and adult life is
discussed to be due to an increase in type I epithelial cells during
alveolarization. Therefore, RAGE expression in the fetal lung is
associated with lung development. Reynolds et al. assessed the
RAGE expression in the mouse lung from embryonic day (E) 13.5
onwards. RAGE is expressed initially in undifferentiated parench-
ymal cells in the saccular stage (E17.5-PN5). A persistent RAGE
expression is detected just before birth at E18.5. A remarkable
upregulation of RAGE is observed in type I alveolar cells during the
alveolar (PN5–PN20) stage of lung development, demonstrating
once again its association to alveolarization [170]. High RAGE
expression prior to the alveolarization period has deleterious
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Fig. 6. Expression of RAGE in the early rabbit embryo. Transcripts of RAGE were detected in day 3, 4, and 6 p.c. embryos and blastocysts in gastrulation stages 0 (st 0), 1 (st 1),
and 2 (st 2). A probe without cDNA was used as negative control (ntc), cDNA from lung tissue was used as positive control. Internal control was the expression of GAPDH in
all probes (A). Immunohistochemical detection of RAGE in 6 day old rabbit blastocysts. RAGE localization was visualized by peroxidase-diaminobenzidine reaction (brown
color). The nucleus was counterstained with hemalum (blue color). The negative control is the control reaction of the HRP-conjugated secondary goat-anti mouse-IgG. RAGE
is mainly localized in the membrane of embryoblast cells (EB). In trophoblast cells (TB) RAGE is barely present (B) (own unpublished data from EH and BF).
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effects including the development of pulmonary dysplasia
[173,174]. Although RAGE is highly expressed in lung its depletion
does neither mediate serious pulmonary changes nor reduces the
lifespan [175,176]. During aging RAGE is constantly high expressed
in the lung [177]. Interestingly, under pathophysiological condition
RAGE is downregulated in malignant tumor of the lung, what is a
striking paradox, since in many other tumor entities, the pattern of
RAGE expression follows the opposite direction [178,179]. In other
tissues the moderate expression of RAGE can change during aging.
In aged rat hearts Gao et al. found high levels of RAGE and equally
high levels of AGEs, with a NF-kB activation [180]. The increase in
RAGE during aging is possibly due to the accumulation of RAGE
ligands, which in turn upregulates receptor expressions in a
positive feedback loop. Simm et al. also found an age-dependent
upregulation in the protein expression of RAGE in the human heart
tissue with an unaltered level of mRNA suggesting a reduced
turnover of the receptor during aging [181]. In contrast sRAGE, a
splice variant of RAGE, is downregulated in the plasma during
aging [182]. High levels of plasma sRAGE are even assumed to have
positive impact on human longevity [183].
RAGE expression and lung homeostasis
RAGE shows histological presence in pulmonary endothelium,
bronchial and vascular smooth muscle, as well as in alveolar
macrophages and leiomyocytes and on the visceral pleural surface
in bovine tissues [184]. Although it is widely accepted that RAGE is
strongly expressed in the alveolar epithelium cells there are
contradictory results concerning the exact differentiation state of
these cells. However, there is more evidence that RAGE is a marker
for type I alveolar cells rather than type II [185–187]. Within type I
cell, RAGE has been shown to be speciﬁcally localized towards the
basolateral membrane and to be co-localized with markers speciﬁc
to type I alveolar epithelial cells [186,188]
The strong expression of RAGE in the lung suggests a speciﬁc
role of this receptor in maintaining lung homeostasis. Its potential
role during lung development was described earlier. Although
mice lacking RAGE do not show serious pulmonary alterations
[175] several studies indicate adverse effects of RAGE in develop-
ment ﬁbrosis and acute lung injury. Al-Robaiy et al. elucidate the
importance of the high RAGE expression in supporting the
respiratory mechanics of the lung. Lungs from RAGE knockout
(RAGE /) mice show a signiﬁcant increase in dynamic lung
compliance and a decrease in the maximal expiratory air ﬂow
[176]. It is discussed that the biomechanically interaction of cells
and their matrix, as well as the mechanically coupling of cells are
affected. Bartling et al. were the ﬁrst group describing an prefer-
ential localization of RAGE at cell–cell contacts [178]. Based on
these data RAGE was discussed to have an adhesive role. Later it
was found that RAGE indeed enhances the adherence of cells to
matrix proteins and, most remarkably, has an exceptional capacity
to induce cell spreading [186]. The degree of adherence could be
decreased by blocking RAGE. These studies give its apparently
important role in modulating adhesion of alveolar epithelial cells
to the basement membrane. This is important for pathologies like
ﬁbrosis or cancer/metastasis where this is impaired. Beside the
interaction of RAGE with the extracellular matrix, the trans
interaction of RAGE can promote tissue stiffness. This assumption
is supported by the ﬁnding in RAGE /mice that showed lower
elastin mRNA and protein levels [176].
RAGE expression and bone metabolism
Recent studies provide evidence for a contribution of RAGE to
bone remodeling. RAGE is expressed in both osteoclasts and osteo-
blasts [146,148]. In primary cultured bone marrow macrophages
(BMM) RAGE appears to be up-regulated during osteoclast differ-
entiation [148]. BMMs differentiated from RAGE / bone marrow
cultures appear smaller in size compared with cells from WT
cultures, that suggest a morphologic defect in in vitro-differentiated
RAGE / osteoclasts [148]. Zhou and coworkers also found a
reduced integrin-mediated cell adhesion signaling in BMMs. In
RAGE / mice both bone mineral density and bone biomechanical
strength are increased associated with a decreased number of
osteoclasts [147,148]. Ding et al. suggest that the lack of RAGE mainly
decreases the osteoclast function in RAGE / mice and may not
physiologically affect osteoblast function [147] Contrary Philip et al.
show an attenuated gene expression associated with osteoblast
differentiation in RAGE deﬁciency mice [189]. However, there are
more data describing the role of RAGE in osteoclast maturation and
function that generally implicates a role of RAGE in the maturation of
monocyte/macrophage, representing cell lineages of the immune
system.
RAGE and immune response
The upregulation of RAGE in inﬂammatory lesions of various
diseases (rheumatoid arthritis, inﬂammatory kidney disease, arter-
iosclerosis, inﬂammatory bowel disease) and the capacity of
RAGE to bind many proinﬂammatory ligands (amyloid-β ﬁbrils,
S100 proteins, and HMGB1) indicating that RAGE is an important
player in the propagation of immune/inﬂammatory responses.
As the majority of components in the innate immune system,
the encoding gene for RAGE (Ager) is localized within the major
histocompatibility (MHC) class III [190]. RAGE is known to be
expressed on numerous immune cells including neutrophils,
monocytes/macrophages, lymphocytes and dentritic cells [184].
Liliensiek and coworkers identiﬁed RAGE/ mice are protected
from the lethal effects of septic shock, which is largely based on
the innate immune response. RAGE/ mice show reduced local
inﬂammation and decreased NF-κB activation in target organs of
septic shock [191]. Blockage of RAGE causes a retarded inﬂamma-
tory response by arresting central inﬂammation signaling path-
ways [192,193]. RAGE activation on endothelium, mononuclear
phagocytes, and lymphocytes triggers cellular activation, with
releasing of key proinﬂammatory mediators [192]. Chavaki et al.
found RAGE to be a counter-receptor for the leukocyte integrin
Mac-1, thus being directly involved in leukocyte recruitment. The
interaction of RAGE on leukocytes results in activation of sustained
NF-κB-dependent gene expression [56]. Recently, RAGE has been
identiﬁed to form a complex with Toll-like receptor 9 (TLR9), the
principal DNA-recognizing receptor. This RAGE–TLR9 complex is
able to detect pathogen DNA [65]. Regarding to these ﬁndings,
Sirosis et al. show that the RAGE lowers the immune recognition
threshold for the activation of TLR9 and promotes DNA uptake into
endosomes. In vivo experiments show that RAGE / mice are
unable to mount a typical inﬂammatory response to DNA in the
lung [194]. The data supporting the role of RAGE in adaptive
immune response are much weaker than those focused on the
innate immunity. However, several ﬁndings have been recently
reported. The sRAGE administration in naive mice leads to an
inﬂux of lymphocytes into the spleen and a reducing B-cell
number in the bone marrow. Furthermore, sRAGE causes the
activation and maturation of B cells resulting in a higher secretion
of IgM and IgG and leads to the activation of T cells, as conﬁrmed
by the increased production of cytokines [195]. The absence of
RAGE is manifest by reduced activation of T cells to alloantigens
in vivo and in vitro. RAGE is involved in the differentiation of T cells
along a Th1 phenotype and RAGE mRNA is more abundant in Th1
compared with Th2 cells [61].
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RAGE expression and neuronal differentiation
RAGE expression in cell bodies and axonal processes was ﬁrst
observed in the bovine nervous system in motor neurons and in
certain populations of cortical neurons [184]. Ligands for RAGE in the
central nervous system are HMGB1, S100B, AGEs, and amyloid-β
ﬁbrils. The interaction of RAGE with AGEs or amyloid-β ﬁbrils leads
primarily to inﬂammation and oxidative stress and is involved in the
pathogenesis of some neurological disorders i.e., Alzheimer0s disease
[196–199], whereas HMGB1 and S100B are known to be involved in
numerous neuronal functions, including neurite outgrowth, migra-
tion, differentiation and survival. However, the concentration of
ligands seems be an important factor in predicting the effect of
RAGE on cellular homeostasis. Low concentrations lead to more
beneﬁcial events (neurite outgrowth) and high concentrations,
inducing more deleterious events (inﬂammatory signaling) [200].
Besides the concentration, also the cell type seems to be important.
In neurons, the binding of HMGB1 results in neurite outgrowth,
while in microglia HMGB1 induces potentially deleterious inﬂam-
matory signaling [201]. The multiple effects of RAGE involved it in
nerve regeneration through recruitment of both inﬂammatory, in
part mediated throughmacrophage activation, and axonal outgrowth
pathways [202]. Blocking of RAGE suppresses peripheral nerve
regeneration, reduces the functional recovery of the nerve and
decreases the number of inﬁltrating phagocytes [203].
Prevention of AGE formation
As already mentioned, the AGE pool in cells, tissues and body
ﬂuids is a result from the interaction of dietary AGEs, formation of
endogenous AGE and the renal clearance. While intake of dietary
AGEs and AGEs from cigarettes plays also a role in cellular AGE
levels, a reduction in AGE-uptake would decrease plasma levels.
Otherwise Somoza et al. have demonstrated that bread crust,
pronyl-BSA and dietary malt are able to improve the activity of
chemopreventive enzymes and antioxidant capacity. They suggest,
that the positive effects rely on compounds known as melanoi-
dine, which are responsible for the activation of Phase II enzymes,
such as glutathione-S-transferase [204]. Moreover, several studies
have shown that melanoidine have the ability to increase the
proliferation of biﬁdobacteria [205,206]. The bioavailability of
dietary AGEs can only be assumed. How and which structures of
melanoidine are responsible for the induction of Phase II enzymes
is not known yet and needs to be further investigated. According
to the ﬁrst analysis of Pötzsch et al. a separation of AGEs into high
molecular weight (HMW41 kDa) and low molecular weight
(LMWo1 kDa) compounds shows that the LMW fraction leads
to an inhibition of intracellular oxidation but differs from the cell
lines that were used [207]. However, for the AGE-toxicity the
endogenously formed AGEs are of more importance and their
elimination is imperative to avoid the development of AGE-
mediated diseases. For early detoxiﬁcation proteins, such as
defensins, lactoferrin and lysozyme circulate in blood and body
ﬂuids. They all depend to the innate defense system and are able
to bind AGEs before cellular uptake or cross-linking to other
molecules [83,208,209]. Therefore, Zheng et al. describe an accel-
eration of renal AGE-clearance and a suppression of intracellular
AGE-mediated signaling by lysozymes, suggesting that lysozymes
sequestered AGEs and protect proteins for further damage [210]. In
conclusion, AGEs are metabolized by innate defense and/or intra-
cellular degradation after receptor-dependent uptake [209]. For
the AGE-uptake different receptors have been investigated which
have been described in detail above. Two main systems are
responsible for the intracellular degradation of damaged and
modiﬁed proteins, lipids and nucleic acids, the proteasomal and
the lysosomal system. Therefore, Grimm et al. found out that AGEs
can alter the assembly of the proteasome [30]. Normally, the 20S
core of the proteasome consists of two outer α- and inner β-rings,
where the β subunits, β5 (chymotrypsin-like activities), β1 (pepti-
dyl-glutamyl-peptide-hydrolyzing or caspase-like activity) and β2
(trypsin-like activity) are responsible for the proteolytical activity
of the proteasome [31]. After treatment of RAW 264.7 cells with
AGEs, a decrease of the constitutive proteasomal β-subunits and an
increase in the inducible immunoproteasomal β-subunits β5i, β1i
and β2i have been shown. The induction of immunoproteasomal
subunits demonstrates the involvement of AGEs in immune
response. Thereby, the immunoproteasome has the ability to
process proteins to peptides which are later presented on the
surface of MHC class I molecules [211]. It is also discussed whether
the immunoproteasome is able to remove oxidized proteins which
accumulate after oxidative stress [212]. Due to the fact that the
proteasome is unable to degrade the complex structures of the
AGEs [138,213], the lysosomal system plays the main part in
detoxiﬁcation. Further, Grimm et al. have demonstrated that
cathepsins, especially cathepsin D plays a major role in intracel-
lular degradation of modiﬁed AGEs [139].
Enzymatic degradation of AGE-precursors, such as α-
oxalaldehydes is also important in prevention of AGE formation
[22,209]. The glyoxalase system as well as aldehyde dehydrogen-
ase are described to detoxiﬁed early sugar adducts and reactive
carbonyl compounds, such as glyoxal and methylglyoxal [214,215].
The cytosolic glyoxalase system, consisting of glyoxalase I and II, is
responsible for converting reactive acyclic α-oxalaldehydes into to
α-hydoxyacids. Under normal conditions α-oxalaldehydes, such as
methylglyoxal spontaneously form a hemiacetal with glutathione.
Then glyoxalase I catalyzes the hemiacetal further to S-2-
hydroxyacylglutathione. Subsequently, glyoxalase II converted
S-2-hydroxyacylglutathione to α-hydoxyacids and glutathione.
Thereby, the glyoxalase system prevents the accumulation of
reactive α-oxalaldehydes and suppresses further rearrangements
of these reactive compounds. The reactions are proportional to the
glutathione level in the cytosol [216]. When glutathione levels are
low due to increased oxidative stress, the detoxiﬁcation via the
glyoxalase system is impaired [37]. Furthermore, it was suggested
that hyperglycemia; methylglyoxal and other RAGE ligands
signiﬁcantly reduce glyoxalase I activity in endothelia and neuro-
nal cells as well as in cultured ﬁbroblasts. An inhibition of RAGE
restores the activity of glyoxalase I [143,217].
Another enzyme for metabolizing further glycation adducts is
fructosamie 3-phosphokinase (F3NK). It is responsible for the
phosphorylation of free fructosamine into the AGE-precursor
3-deoxyglucosone. This reactive carbonyl compound needs to be
detoxiﬁed also to interrupt the vicious cycle of AGE formation
[168]. For hemoglobin, it was demonstrated that glycation
increased during incubation with high glucose concentrations
and the parallel inhibition of F3NK in human erythrocytes. Thus,
it is assumed that F3NK plays an important role in prevention of
further glycation processes [218].
Due to the involvement of oxidants and metals, such as iron and
cooper in the formation of AGEs, the search for antioxidative and
chelating nutrients is of increasing interest [42]. The use of desfer-
oxamine as iron chelator and anti-inﬂammatory compounds, such as
acetylsalicylic acid have been described to inhibit further glycation
processes [219]. The ﬁnal elimination of degraded AGEs is carried out
by the kidney; however these processes are also not well understood.
Conclusion
The review has shown the various impacts of AGEs and their
ability to directly alter protein function, forming involved in many
C. Ott et al. / Redox Biology 2 (2014) 411–429424
chronic diseases. The heterogeneous group of AGEs and the variety
of receptor-mediated uptake into cells lead to the activation of
many signaling cascades, gene expression as well as to the
processing and elimination of AGEs and differs in the various cell
types. For the cellular uptake and response a number of AGE
receptors have been identiﬁed but their internalization and
physiological roles are not yet fully understood. From all the
evidence presented in this review, it is obvious that RAGE plays
a vital role in normal physiology. On a closer look to its involve-
ment in physiological processes it is noticeable that RAGE is most
often implicated in the immune response of the respective organ:
osteoclast function in the bone, activation of microglia in the
nervous system and activation of literal immune cells for immune
response. However, beside these roles, RAGE is identiﬁed to have
various speciﬁc effects in different organs. As RAGE is most often
discussed to induce deleterious effects and many animal studies
showed beneﬁcial effects in clinical settings by blocking RAGE,
RAGE is suggested as pharmaco-therapeutic target. Changes in
receptor activity and the reciprocal effects of receptor-mediated
AGE signaling and detoxiﬁcation during the aging process is yet to
be established. Impaired detoxiﬁcation and elimination of AGEs is
associated with cytotoxicity, apoptosis and increased inﬂamma-
tory response. Besides the fact that AGEs are inducible under
increased ROS levels, they are able to induce ROS, leading to an in
vicious cycle. In addition to the negative effects of AGEs, positive
effects have also been described. However, there are still critical
issues that remain to be resolved before a RAGE-directed ther-
apeutic strategy can be established. Future investigations are
deﬁnitely required to develop a greater understanding of the
impact of RAGE on physiological processes.
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